Results 11 to 20 of about 192,487 (273)

Therapeutic methods and effect on keloid and hypertrophic scars: a systematic review [PDF]

Frontiers in Medicine
BackgroundKeloids and hypertrophic scars are fibroproliferative disorders with high recurrence rates, lacking a definitive treatment standard. This review systematically evaluates current therapies and their effectiveness in treating keloid and ...
Yuhang Shen, Lirong Yang, Dayong Feng, Chunhui Wang, Zhiyong Bai, Xi Wang, Jingwen Wang, Yuening Feng, Ayue An   +8 more
doaj   +2 more sources

Quantum Chemical Properties of Fluorouracil/XZn11O12 (X = Zn, Cu, Fe, Ni) Nanocomplexes and Interactions with Human Serum Albumin [PDF]

ChemistryOpen
This research focused on structural, electronic, and interaction properties of fluorouracil (5‐FU) adsorbed on transition metal (TM)‐doped ZnO nanoclusters (XZn11O12, where X = Zn, Cu, Fe, Ni) using density functional theory (DFT) at the B3LYP/LANL2DZ ...
Mohan Bahadur Kshetri, Navin Sharma, Kamal Khanal, Madhav Prasad Ghimire, Tika Ram Lamichhane   +4 more
doaj   +2 more sources

A Pilot Study of Peritumor Administration of 5-FU for Preventing Bleeding in Advanced Gastric Cancer

The Korean Journal of Gastroenterology, 2022
Five-FU is a potent chemotherapeutic agent for suppressing endothelial cell growth. The purpose of this study was to investigate the usefulness of local peritumor injection of 5-FU for patients with advanced gastric cancer (AGC) for the prevention of ...
Nam-Hee Kim, Jung Ho Park, Dong-Hoe Koo, Yoon Suk Jung, Hee-Young Lee   +4 more
doaj   +1 more source

Evaluating predictive pharmacogenetic signatures of adverse events in colorectal cancer patients treated with fluoropyrimidines [PDF]

, 2013
The potential clinical utility of genetic markers associated with response to fluoropyrimidine treatment in colorectal cancer patients remains controversial despite extensive study.
A Fariña-Sarasqueta, A Loganayagam, A Ruzzo, A Ruzzo, A Yawata, A Zaniboni, Andreas-Claudius Hoffmann, Ann Barrett, B Glimelius, BA Jennings, Barbara A. Jennings, C Fernandez-Rozadilla, C Zhang, CE de Bock, CF Thorn, D Caronia, Daniel Epurescu, DB Longley, E Hitre, E Van Cutsem, G Willis, Gavin S. Chu, Gavin Willis, H Gellekink, H Taflin, I Weisberg, J Cassidy, Jane Skinner, K Derwinger, K Kawakami, K Kawakami, L Peter, L Sharp, M Boisdron-Celle, M Gusella, M Scartozzi, M Schwab, M Vignoli, ME Fernández-Contreras, Melanie Keane, MJ Deenen, MS Braun, MV Mandola, MV Mandola, MV Mandola, N Horie, P Frosst, R Pullmann Jr., RA Goodwin, Richard Turner, S Afzal, S Afzal, S Kaneda, T André, TV Perneger, V Sulzyc-Bielicka, W Ichikawa, W Scheithauer, WG Johnson, Yoon K. Loke   +59 more
core   +16 more sources

Hypertriglyceridemia Induced by Fluorouracil: A Novel Case Report

Case Reports in Oncology, 2021
We had previously reported on S-1-induced hypertriglyceridemia. Here, we report fluorouracil-induced hypertriglyceridemia in a patient with capecitabine-induced hypertriglyceridemia and the corresponding therapeutic process.
Yoshitaka Saito, Yoh Takekuma, Satoshi Yuki, Yoshito Komatsu, Mitsuru Sugawara   +4 more
doaj   +1 more source

PHYSIOLOGICAL AND BIOCHEMICAL CHANGES FOR 5- FLUOROURACIL DRUG (ANTI-CANCER) IN CANCER PATIENTS [PDF]

Basrah Journal of Veterinary Research, 2017
The study was conducted to determine the effect of the 5-Fluorouracil (5-FU) drug is a medication used to treat cancer or the knowledge of 5-FU drug(anticancer) effect might help to attribute these side on physiological and biochemical parameters in ...
Baida R. Ali
doaj   +1 more source

5-Fluorouracil degradation rate as a predictive biomarker of toxicity in breast cancer patients treated with capecitabine [PDF]

, 2020
Capecitabine is an oral prodrug of 5-fluorouracil with a relevant role in the treatment of breast cancer. Severe and unexpected toxicities related to capecitabine are not rare, and the identification of biomarkers is challenging.
Botticelli, A., Cerbelli, B., Lionetto, L., Marchetti, P., Roberto, M., Scagnoli, S., Simmaco, M.   +6 more
core   +1 more source

MicroRNA-sensitive oncolytic measles virus for chemovirotherapy of pancreatic cancer

Molecular Therapy: Oncolytics, 2021
Advanced pancreatic cancer is characterized by few treatment options and poor outcomes. Oncolytic virotherapy and chemotherapy involve complementary pharmacodynamics and could synergize to improve therapeutic efficacy.
Hans Martin Singh, Mathias Felix Leber, Sascha Bossow, Christine E. Engeland, Jan Dessila, Christian Grossardt, Karim Zaoui, John C. Bell, Dirk Jäger, Christof von Kalle, Guy Ungerechts   +10 more
doaj   +1 more source

Transient Receptor Potential Cation Channel Subfamily V Member 1 Expression Promotes Chemoresistance in Non-Small-Cell Lung Cancer

Frontiers in Oncology, 2022
Approximately 85% of lung cancer cases are non-small-cell lung cancer (NSCLC). Chemoresistance is a leading cause of chemotherapy failure in NSCLC treatment.
Li Li, Cheng Chen, Qin Xiang, Songqing Fan, Tian Xiao, Yangchao Chen, Duo Zheng   +6 more
doaj   +1 more source

Modified bi‐weekly cetuximab‐cisplatin and 5‐FU/leucovorin based regimen for effective treatment of recurrent/metastatic head and neck squamous cell carcinoma to reduce chemotherapy exposure of patients

Cancer Reports, 2022
Background The standard chemotherapy treatment protocol for patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) requires as long as 56 days of hospitalization over six months. Where the 5‐Fluorouracil (5‐FU) pump is available,
Amichay Meirovitz, Shani Bergerson, Nir Hirshoren, Jeffrey M. Weinberger, Evgeniya Bersudski, Sharon Daniel, Kim Sheva, Cesar A. Perez   +7 more
doaj   +1 more source